XML 37 R24.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Equity Incentive Plans | 12 Months Ended
--- | ---
Jun. 30, 2022
Share-Based Payment Arrangement [Abstract] |
Equity Incentive Plans | 16. Equity Incentive Plans Aytu 2015 Plan. On June 1, 2015, the Company’s stockholders approved the Aytu BioPharma 2015 Stock Option and Incentive Plan (the “Aytu 2015 Plan”), which, as amended in July 2017, provides for the award of stock options, stock appreciation rights, restricted stock, and other equity awards. On February 13, 2020, the Company’s stockholders approved an increase to 5.0 million total shares of common stock in the Aytu 2015 Plan. The shares of common stock underlying any awards that are forfeited, canceled, reacquired by Aytu prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the Aytu 2015 Plan will be added back to the shares of common stock available for issuance under the Aytu 2015 Plan. Stock options granted under this plan have contractual terms of 10 years from the grant date and a vesting period ranging from 3 to 4 years. The restricted stock awards have a vesting period ranging from 4 to 10 years, and the restricted stock units have a vesting period 4 years. As of June 30, 2022, the Company had 2,383,061 shares available for grant under the Aytu 2015 Plan. Neos 2015 Plan. Pursuant to the Neos Acquisition, the Company assumed 69,721 stock options and 35,728 restricted stock units (RSUs) previously granted under Neos plan. Accordingly, on April 19, 2021, the Company registered 105,449 shares of its common stock under the Neos Therapeutics, Inc. 2015 Stock Options and Incentive Plan (the "Neos 2015 Plan") with the SEC. The terms and conditions of the assumed equity securities will stay the same as they were under the previous Neos plan. The Company allocated costs of the replacement awards attributable to pre- and post-combination service periods. The pre-combination service costs were included in the considerations transferred. The remaining costs attributable to the post-combination service period are being recognized as stock-based compensation expense over the remaining terms of the replacement awards. Stock options granted under this plan have contractual terms of 10 years from the grant date and a vesting period ranging from 1 to 4 years. As of June 30, 2022, the Company had 45,294 shares available for grant under the Neos 2015 Plan. Stock Options Stock option activity is as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  |  |  | ​ | ​ |  | Weighted
​ | ​ | ​ | ​ | ​ | ​ | ​ | Average
​ | ​ | ​ | ​ | Weighted | ​ | Remaining
​ | ​ | Number of | ​ | Average | ​ | Contractual
​ | ​ | Options | ​ | Exercise Price | ​ | Life in Years
Outstanding June 30, 2021 |  | 109,588 | ​ | $ | 14.52 |  | 8.07
Forfeited/Cancelled |  | (15,569) | ​ | ​ | 7.98 |  |
Expired |  | (13,642) | ​ | ​ | 9.65 |  |
Outstanding at June 30, 2022 |  | 80,377 | ​ | $ | 16.61 |  | 7.77
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Exercisable at June 30, 2022 |  | 54,649 | ​ | $ | 20.58 |  | 7.77
​ The following table details the options outstanding at June 30, 2022 by range of exercise prices: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ |  |  |  | ​ | ​ |  | Weighted |  |  |  | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Average | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Remaining | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | Weighted | ​ | Contractual | ​ | ​ | ​ | ​ | ​
Range of | ​ | Number of | ​ | Average | ​ | Life of | ​ | Number of | ​ | Weighted
Exercise | ​ | Options | ​ | Exercise | ​ | Options | ​ | Options | ​ | Average
Prices | ​ | Outstanding | ​ | Price | ​ | Outstanding | ​ | Exercisable | ​ | Exercise Price
$ | 6.2 - 9.70 |  | 38,998 | ​ | $ | 6.44 |  | 7.65 |  | 19,882 | ​ | $ | 6.50
$ | 9.80 - 14.70 |  | 41,225 | ​ | $ | 14.13 |  | 7.90 |  | 34,613 | ​ | $ | 14.28
$ | 2,800.00 - 4,200.00 |  | 154 | ​ | $ | 3,255.06 |  | 3.80 |  | 154 | ​ | $ | 3,255.06
​ | ​ |  | 80,377 | ​ | $ | 16.61 |  | 7.77 |  | 54,649 | ​ | $ | 20.58
​ No stock options were granted during the year ended June 30, 2022. The weighted-average grant date fair value of options granted during the years ended June 30, 2022 and June 30, 2021 was $0 and $3.81, respectively. As of June 30, 2022, there was $0.2 million of total unrecognized compensation cost adjusted for estimated forfeitures, related to non-vested stock options granted under the Company’s equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.6 years. Restricted Stock During the year ended June 30, 2022, the Company granted a total of 295,000 shares of restricted stock, with certain accelerated vesting conditions, to members of its management team pursuant to the Aytu 2015 Plan, of which 1/3 vest on the grant date and 1/12 on the first day of each quarter thereafter, subject to continuing employment with the Company through each vesting date. These restricted stock grants have a grant date fair value ranging from $2.65 per-share to $4.02 per-share. Restricted stock activity under the Aytu 2015 Plan is as follows: ​
​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Weighted
​ | ​ | ​ | ​ | Average Grant
​ | ​ | Number of | ​ | Date Fair
​ | ​ | Shares | ​ | Value
Unvested at June 30, 2021 |  | 1,955,268 | ​ | $ | 7.83
Granted |  | 295,000 | ​ | ​ | 3.67
Vested |  | (642,696) | ​ | ​ | 6.81
Unvested at June 30, 2022 |  | 1,607,572 | ​ | $ | 7.47
​ As of June 30, 2022, there was $9.6 million of total unrecognized compensation costs adjusted for estimated forfeitures, related to non-vested restricted stock granted under the Company’s equity incentive plan. The unrecognized compensation cost is expected to be recognized over a weighted average period of 2.7 years. The total fair value of restricted stock vested during the year ended June 30, 2022 was $1.6 million. The Company previously issued 158 shares of restricted stock outside of the Aytu 2015 Plan, which vest in July 2026. On January 17, 2022, the Company granted 100,000 shares of restricted stock to a member of its management team outside of the Aytu 2015 Plan, of which 1/3 vest on January 17, 2023 and 1/12 each quarter thereafter, subject to continuing employment with the Company through each vesting date until January 17, 2025. This restricted stock grant has a grant date fair value of $1.35 per-share. As of June 30, 2022, there was $0.9 million total unrecognized costs adjusted for estimated forfeitures, related to non-vested restricted stock outside of the Company’s equity incentive plan. The unrecognized compensation cost is expected to be recognized over a weighted average period of 3.4 years. Restricted Stock Units The year ended June 30, 2022, the Company granted a total of 170,000 shares of restricted stock units (“RSUs”), to members of its management pursuant team to the Aytu 2015 Plan, of which 1/3 vest on the grant date and 1/12 on the first day of each quarter thereafter, subject to continuing employment with the Company through each vesting date. These RSUs have grant date fair value ranging from $1.06 per share to $1.86 per-share. RSUs activity is as follows: ​
​ | ​ | ​ | ​ | ​ | ​
​ |  |  |  | ​ | ​
​ | ​ | ​ | ​ | Weighted
​ | ​ | ​ | ​ | Average Grant
​ | ​ | Number of | ​ | Date Fair
​ | ​ | Shares | ​ | Value
Unvested at June 30, 2021 |  | 78,318 | ​ | $ | 7.20
Granted | ​ | 170,000 | ​ | ​ | 1.29
Vested |  | (15,396) | ​ | ​ | 6.20
Forfeited | ​ | (62,922) | ​ | ​ | 7.44
Unvested at June 30, 2022 |  | 170,000 | ​ | $ | 1.29
​ As of June 30, 2022, there was $0.2 million of total unrecognized compensation costs adjusted for estimated forfeitures, related to non-vested RSUs granted under the Company’s equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 2.6 years. The total fair value of RSUs vested during the year ended June 30, 2022 was $0.1 million. Stock-based compensation expense related to the fair value of stock options and restricted stock and RSUs was included in the statements of operations as set forth in the below table: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Year Ended
​ | ​ | June 30,
​ | ​ | 2022 |  | 2021
​ | ​ | (In thousands)
Cost of sales | ​ | $ | 31 | ​ | $ | 16
Research and development | ​ | ​ | 536 | ​ | ​ | 68
Selling and marketing | ​ | ​ | 24 | ​ | ​ | 27
General and Administrative | ​ |  | 4,657 | ​ |  | 3,463
Total stock-based compensation expense | ​ | $ | 5,248 | ​ | $ | 3,574
​

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI https://asc.fasb.org/topic&trid=2228938 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (l) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(2) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration